BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 29548582)

  • 1. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison Between Esophagectomy and Definitive Chemoradiotherapy in Patients With Esophageal Cancer.
    Wang BY; Hung WH; Wu SC; Chen HC; Huang CL; Lin CH; Chen HS
    Ann Thorac Surg; 2019 Apr; 107(4):1060-1067. PubMed ID: 30571951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Wang BY; Wu SC; Chen HC; Hung WH; Lin CH; Huang CL; Chen HS
    Br J Surg; 2019 Feb; 106(3):255-262. PubMed ID: 30395362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
    Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T
    Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre- versus postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Hsu PK; Chen HS; Liu CC; Huang CS; Hsieh CC; Hsu HS; Wu SC
    J Thorac Cardiovasc Surg; 2017 Aug; 154(2):732-740.e2. PubMed ID: 28457536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.
    Kawai T; Kochi M; Fujii M; Song K; Hagiwara K; Watanabe M; Matsuno Y; Suda H; Yagi R; Takayama T
    Anticancer Res; 2017 Jun; 37(6):3301-3306. PubMed ID: 28551681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative adjuvant chemotherapy versus chemoradiotherapy for node-positive esophageal squamous cell carcinoma: a propensity score-matched analysis.
    Wang Q; Lang J; Li T; Peng L; Dai W; Jiang Y; Xie T; Fang Q; Wang Y; Wu L; Cao B; Han Y
    Radiat Oncol; 2020 May; 15(1):119. PubMed ID: 32448253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
    J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
    Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
    Chen CY; Li CC; Chien CR
    World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
    Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitive chemoradiation therapy or surgery for clinical T1-3N0-1M0 thoracic esophageal squamous cell carcinoma: A propensity score matching analysis.
    Li XY; Luo HS; Wu SX; Du ZS; Zheng CP; Wu ZY
    Asian J Surg; 2019 Jan; 42(1):350-355. PubMed ID: 29802029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
    Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
    Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
    Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
    Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.